Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trialHuijie Bian, Ye Zhang, Jianqi Lian et al.|Signal Transduction and Targeted Therapy|2021Cited by 66
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Xiaofeng Zeng, Ying Jiang et al.|Annals of the Rheumatic Diseases|2025Cited by 17